For the first target addressed in the partnership, the two companies reported the successful delivery of AI-designed, ...

SERB Pharmaceuticals plans to buy Y-mAbs Pharmaceuticals in a $412 million all-cash deal. CorMedix bought Melinta ...

The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as ...

Hong Kong-based CSPC will receive $120 million from Madrigal under the deal. Elsewhere, Apellis and PTC Therapeutics won FDA ...

USA-based Madrigal Pharmaceuticals today announced that it has entered into an exclusive global license agreement with CSPC ...

U.S. drugmaker Madrigal Pharmaceuticals has struck a licensing deal with CSPC Pharmaceutical Group that could be worth more than $2 billion for the Chinese company if it results in a new drug for a ...

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

Madrigal Pharmaceuticals said on Wednesday it has entered into a licensing agreement worth up to $2 billion with China's CSPC Pharmaceutical Group to develop an oral GLP-1 drug for a serious form of ...

The AstraZeneca PLC ADR AZN slid 1.14% to $71.83 Monday, on what proved to be an all-around mixed trading session for the stock market, with the NASDAQ Composite Index COMP rising 0.33% to 21,178. ...

AstraZeneca AZN is gearing up to announce its quarterly earnings on Tuesday, 2025-07-29. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI (durvalumab) has been accepted and granted Priority Review in the U.S. for the treatment of patients with resectable, ...